Newsfile Corp
13 Jun 2026, 14:13 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The FDA issued a Complete Response Letter (CRL) rejecting Disc Medicine's new drug application for its bitopertin program due to insufficient evidence. — FDA rejection of a primary drug candidate is a major fundamental setback that directly impairs a biotech company's valuation and growth prospects.
-0.80The Rosen Law Firm is investigating potential securities claims and preparing a class action lawsuit against Disc Medicine for allegedly issuing misleading business information. — Class action litigation creates additional legal liabilities and reputational risk, though it is often a secondary effect of the initial FDA failure.
-0.30Which stocks this story touches
Facing a class action lawsuit following an FDA Complete Response Letter and a 22% stock price drop.
Continue reading
6 related stories
Top 3 movers · tap to explore
Mentioned as the subject of a securities class action lawsuit.
Mentioned as the subject of a securities class action lawsuit with an upcoming deadline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
